Glymidine sodium
![]() | |
Systematic (IUPAC) name | |
---|---|
N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide | |
Clinical data | |
Oral | |
Pharmacokinetic data | |
Bioavailability | High |
Protein binding | 90% |
Half-life | 3.8 hours |
Identifiers | |
339-44-6 ![]() | |
A10BC01 | |
PubChem | CID 9565 |
DrugBank |
DB01382 ![]() |
ChemSpider |
9190 ![]() |
UNII |
4C5I4BQZ8F ![]() |
ChEMBL |
CHEMBL1697838 ![]() |
Chemical data | |
Formula | C13H15N3O4S |
309.34 g/mol | |
SMILES
| |
| |
![]() |
Glymidine sodium (INN, also known as glycodiazine; trade name Gondafon) is a sulfonamide antidiabetic drug, structurally related to the sulfonylureas. It was first reported in 1964, and introduced to clinical use in Europe in the mid to late 1960s.[1]
References
- ↑ [No authors listed] (June 1967). "Glymidine". Br Med J 2 (5555): 817. doi:10.1136/bmj.2.5555.817. PMC 1843097. PMID 6029147.